{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:52:55Z","timestamp":1792662775771,"version":"4.5.0"},"reference-count":47,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.3800","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T15:32:05Z","timestamp":1617204725000},"page":"e213800","source":"Crossref","is-referenced-by-count":64,"title":["Estimated Costs and Long-term Outcomes of Patients With High-Risk Non\u2013Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Gu\u00e9rin in the Veterans Affairs Health System"],"prefix":"10.1001","volume":"4","author":[{"given":"Stephen B.","family":"Williams","sequence":"first","affiliation":[{"name":"Division of Urology, Department of Surgery, University of Texas Medical Branch, Galveston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Howard","sequence":"additional","affiliation":[{"name":"Durham Veterans Affairs Health Care System, Durham, North Carolina"},{"name":"Biostatistics Shared Resource, Duke Cancer Institute, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan L.","family":"Foster","sequence":"additional","affiliation":[{"name":"Durham Veterans Affairs Health Care System, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Klaassen","sequence":"additional","affiliation":[{"name":"Section of Urology, Department of Surgery, Augusta University, Medical College of Georgia, Augusta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Sieluk","sequence":"additional","affiliation":[{"name":"Merck & Co, Inc, Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M.","family":"De Hoedt","sequence":"additional","affiliation":[{"name":"Durham Veterans Affairs Health Care System, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Freedland","sequence":"additional","affiliation":[{"name":"Durham Veterans Affairs Health Care System, Durham, North Carolina"},{"name":"Department of Urology, Cedars-Sinai Medical Center, Los Angeles, California"},{"name":"Center for Integrated Research on Cancer and Lifestyle, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"issue":"1","key":"zoi210138r1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.v70.1","article-title":"Cancer statistics, 2020.","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"7A","key":"zoi210138r2","first-page":"225","article-title":"NCCN urothelial cancer practice guidelines.","volume":"12","author":"Scher","year":"1998","journal-title":"Oncology (Williston Park)"},{"issue":"4","key":"zoi210138r3","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non\u2013muscle invasive bladder cancer: AUA\/SUO guideline.","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"4","key":"zoi210138r4","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU guidelines on non\u2013muscle-invasive urothelial carcinoma of the bladder: update 2013.","volume":"64","author":"Babjuk","year":"2013","journal-title":"Eur Urol"},{"issue":"6","key":"zoi210138r5","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","article-title":"Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.","volume":"178","author":"Hall","year":"2007","journal-title":"J Urol"},{"issue":"2","key":"zoi210138r6","doi-asserted-by":"publisher","first-page":"E51","DOI":"10.1111\/bju.2013.112.issue-2","article-title":"Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades.","volume":"112","author":"Zehnder","year":"2013","journal-title":"BJU Int"},{"issue":"1","key":"zoi210138r7","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/j.clgc.2016.06.014","article-title":"Association between number of endoscopic resections and utilization of bacillus Calmette-Gu\u00e9rin therapy for patients with high-grade, non\u2013muscle-invasive bladder cancer.","volume":"15","author":"Lenis","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"zoi210138r8","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? a meta-analysis of randomized trials.","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"issue":"4","key":"zoi210138r9","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Gu\u00e9rin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"issue":"5","key":"zoi210138r10","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"issue":"23","key":"zoi210138r11","doi-asserted-by":"publisher","first-page":"5392","DOI":"10.1002\/cncr.v117.23","article-title":"Compliance with guidelines for patients with bladder cancer: variation in the delivery of care.","volume":"117","author":"Chamie","year":"2011","journal-title":"Cancer"},{"issue":"10083","key":"zoi210138r12","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1016\/S0140-6736(17)30874-7","article-title":"Evolution and patterns of global health financing 1995-2014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries.","volume":"389","author":"Global Burden of Disease Health Financing Collaborator Network","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"zoi210138r13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010-2020.","volume":"103","author":"Mariotto","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"zoi210138r14","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1200\/JCO.2010.31.1217","article-title":"Cost implications of the rapid adoption of newer technologies for treating prostate cancer.","volume":"29","author":"Nguyen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"24","key":"zoi210138r15","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1200\/JCO.2016.66.6313","article-title":"Use and costs of disease monitoring in women with metastatic breast cancer.","volume":"34","author":"Accordino","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi210138r16","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.eururo.2017.07.016","article-title":"Variations in the costs of radical cystectomy for bladder cancer in the USA.","volume":"73","author":"Leow","year":"2018","journal-title":"Eur Urol"},{"issue":"1","key":"zoi210138r17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.v69.1","article-title":"Cancer statistics, 2019.","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"16","key":"zoi210138r18","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non\u2013muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group.","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi210138r19","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non\u2013muscle-invasive bladder cancer: recommendations from the IBCG.","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol"},{"issue":"5","key":"zoi210138r20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"2","key":"zoi210138r21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The eighth edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging.","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"zoi210138r22","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology guidelines on non\u2013muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u20142019 update.","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"issue":"3","key":"zoi210138r23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrurol.2018.2","article-title":"A practical guide to bladder cancer pathology.","volume":"15","author":"Comp\u00e9rat","year":"2018","journal-title":"Nat Rev Urol"},{"issue":"1","key":"zoi210138r24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.eururo.2012.09.063","article-title":"ICUD-EAU International Consultation on Bladder Cancer 2012: pathology.","volume":"63","author":"Amin","year":"2013","journal-title":"Eur Urol"},{"issue":"8","key":"zoi210138r25","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1097\/PAS.0000000000000240","article-title":"Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference.","volume":"38","author":"Amin","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"zoi210138r26","doi-asserted-by":"publisher","first-page":"15S","DOI":"10.1177\/1077558703256485","article-title":"Using average cost methods to estimate encounter-level costs for medical-surgical stays in the VA.","volume":"60","author":"Wagner","year":"2003","journal-title":"Med Care Res Rev"},{"issue":"12","key":"zoi210138r27","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2019.3732","article-title":"Association between bariatric surgery and long-term health care expenditures among veterans with severe obesity.","volume":"154","author":"Smith","year":"2019","journal-title":"JAMA Surg"},{"issue":"1","key":"zoi210138r28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.eururo.2016.03.028","article-title":"Perioperative outcomes, health care costs, and survival after robotic-assisted versus open radical cystectomy: a national comparative effectiveness study.","volume":"70","author":"Hu","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"zoi210138r29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jval.2010.10.006","article-title":"Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003.","volume":"14","author":"Cipriano","year":"2011","journal-title":"Value Health"},{"issue":"1","key":"zoi210138r30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017.","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"zoi210138r32","doi-asserted-by":"publisher","first-page":"446","DOI":"10.6004\/jnccn.2013.0059","article-title":"Bladder cancer.","volume":"11","author":"Clark","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"issue":"17","key":"zoi210138r33","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1002\/cncr.28147","article-title":"Recurrence of high-risk bladder cancer: a population-based analysis.","volume":"119","author":"Chamie","year":"2013","journal-title":"Cancer"},{"issue":"2","key":"zoi210138r34","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1200\/JOP.2011.000480","article-title":"Adjuvant intravesical bacillus Calmette-Gu\u00e9rin therapy and survival among elderly patients with non\u2013muscle-invasive bladder cancer.","volume":"9","author":"Spencer","year":"2013","journal-title":"J Oncol Pract"},{"issue":"14","key":"zoi210138r35","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1002\/cncr.v126.14","article-title":"Potentially avoidable hospitalizations after chemotherapy: differences across Medicare and the Veterans Health Administration.","volume":"126","author":"Gidwani-Marszowski","year":"2020","journal-title":"Cancer"},{"issue":"3","key":"zoi210138r36","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"issue":"1","key":"zoi210138r37","doi-asserted-by":"publisher","first-page":"20.e9","DOI":"10.1016\/j.urolonc.2014.08.016","article-title":"Treatment and survival in patients with recurrent high-risk non\u2013muscle-invasive bladder cancer.","volume":"33","author":"Chamie","year":"2015","journal-title":"Urol Oncol"},{"issue":"3","key":"zoi210138r38","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/JU.0000000000001023","article-title":"Cost-effectiveness of maintenance bacillus Calmette-Gu\u00e9rin for intermediate and high risk nonmuscle invasive bladder cancer.","volume":"204","author":"Sharma","year":"2020","journal-title":"J Urol"},{"issue":"10","key":"zoi210138r39","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1007\/s00345-018-2550-x","article-title":"Evaluating the cost of surveillance for non\u2013muscle-invasive bladder cancer: an analysis based on risk categories.","volume":"37","author":"Mossanen","year":"2019","journal-title":"World J Urol"},{"issue":"2","key":"zoi210138r40","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/bju.2019.123.issue-2","article-title":"Cost-effectiveness of surveillance schedules in older adults with non\u2013muscle-invasive bladder cancer.","volume":"123","author":"Heijnsdijk","year":"2019","journal-title":"BJU Int"},{"issue":"10","key":"zoi210138r41","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jamasurg.2018.1680","article-title":"Comparing survival outcomes and costs associated with radical cystectomy and trimodal therapy for older adults with muscle-invasive bladder cancer.","volume":"153","author":"Williams","year":"2018","journal-title":"JAMA Surg"},{"issue":"8","key":"zoi210138r42","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2019.1629","article-title":"Comparison of costs of radical cystectomy vs trimodal therapy for patients with localized muscle-invasive bladder cancer.","volume":"154","author":"Williams","year":"2019","journal-title":"JAMA Surg"},{"issue":"10","key":"zoi210138r43","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2217\/fon-2019-0817","article-title":"KEYNOTE-676: phase III study of BCG and pembrolizumab for persistent\/recurrent high-risk NMIBC.","volume":"16","author":"Kamat","year":"2020","journal-title":"Future Oncol"},{"issue":"1","key":"zoi210138r44","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non\u2013muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"zoi210138r45","doi-asserted-by":"crossref","DOI":"10.1111\/jgs.16941","article-title":"End-of-life cost trajectories in cancer patients treated by Medicare versus the Veterans Health Administration.","author":"Gidwani","year":"2020","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"zoi210138r46","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/mdc3.2019.6.issue-5","article-title":"Healthcare utilization and costs for patients with Parkinson\u2019s disease after deep brain stimulation.","volume":"6","author":"Stroupe","year":"2019","journal-title":"Mov Disord Clin Pract"},{"issue":"4","key":"zoi210138r47","first-page":"AS54","article-title":"More or less? Methods to compare VA and non-VA health care costs.","volume":"37","author":"Hendricks","year":"1999","journal-title":"Med Care"},{"key":"zoi210138r31","unstructured":"Noone? AM, Howlander? N, Krapcho? M, et al. SEER cancer statistics review, 1975-2015. Updated September 10, 2018. Accessed June 1, 2020. https:\/\/seer.cancer.gov\/archive\/csr\/1975_2015\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2777975\/williams_2021_oi_210138_1616524166.48715.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T15:32:18Z","timestamp":1617204738000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2777975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.3800","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,31]]}}}